The ASCO Post

News and views from the world of clinical oncology and hematology

THE ASCO POST delivers timely and unbiased reports on major oncology meetings across the globe, including ASCO's annual meeting and regional symposia. Additionally, this newspaper-style publication provides readers with important summaries of evidence-based clinical literature from both general and specialty journals (fully sourced with links to original reports); notable research, data, and liter

ature with application in the clinic, including cost considerations/implications; columns from ASCO's membership with perspective on developments in oncology, quality cancer care, technology, electronic health records, and expert opinion on the state and economics of cancer care.

12/06/2023

Samson W. Fine, MD, on Clinical Significance of Atypical Small Acinar and Intraductal Proliferations in the Prostate

Watch now: https://url.bcst.md/r8e

12/05/2023

Value of Some Established Treatment Practices in Chronic Myeloid Leukemia

Learn more: https://url.bcst.md/w6k

12/05/2023

Genetic Testing in Prostate Cancer: Expert Review

Watch now: https://url.bcst.md/0iq

12/04/2023

Incidence of Breast Cancer After False-Positive Mammography

Read more: https://url.bcst.md/42d

12/01/2023

FDA Investigating Risk of T-Cell Malignancy Following CAR T-Cell Therapies

Learn more: https://url.bcst.md/i7a

11/30/2023

From a Small Town in the Rust Belt, Dennis J. Slamon, MD, PhD, Plays a Big Role in Changing the Face of Breast Cancer Treatment

Read more: https://url.bcst.md/zur

11/29/2023

Metastatic Castration-Resistant Prostate Cancer: Efficacy of Anti-PSMA Antibody With Alpha Emitter

Learn more: https://url.bcst.md/jr0

11/28/2023

Two Studies Show Improved Survival With Novel Front-Line Combinations in Advanced Urothelial Carcinoma

Learn more: https://url.bcst.md/tew

11/27/2023

Pembrolizumab Plus Chemotherapy in Pleural Mesothelioma

Read more about phase III trial results: https://url.bcst.md/r55

11/24/2023

Vitamin D Supplements May Help Reduce Chemotherapy-Induced Peripheral Neuropathy

Learn more: https://url.bcst.md/1xr

11/23/2023

Does Bendamustine Exposure Impact Subsequent CAR T-Cell Outcomes in Large B-Cell Lymphoma?

Discover more: https://url.bcst.md/acd

11/22/2023

Antibody-Drug Conjugates of Benefit in Patients With Metastatic Breast Cancer

Learn more about data presented at : https://url.bcst.md/qot

11/21/2023

Enzalutamide With or Without Leuprolide and Leuprolide Alone in Biochemically Recurrent Prostate Cancer

Results from the EMBARK trial, which led to FDA approval: https://url.bcst.md/juh

11/20/2023

Osimertinib With or Without Chemotherapy in EGFR-Mutant Advanced NSCLC

Learn more about the FLAURA2 trial: https://url.bcst.md/e0k

11/16/2023

EGFR-Mutated NSCLC: Update on Patritumab Deruxtecan in Previously Treated Disease

Learn more from Benjamin Besse, MD, PhD: https://url.bcst.md/lea

11/10/2023

Gilberto de Lima Lopes, Jr, MD, MBA, on Lung Cancer Management: Expert Update

Watch now: https://url.bcst.md/v32

11/09/2023

HER2-Positive Gastric/GEJ Adenocarcinoma: Adding Pembrolizumab to Trastuzumab and Chemotherapy

Learn more about the KEYNOTE-811 trial: https://url.bcst.md/4ep

11/08/2023

Adjuvant Doublet vs Active Surveillance in Resected or Ablated High-Risk HCC

Learn more: https://url.bcst.md/9vn

11/07/2023

Tumor Debulking in Patients With Metastatic Colorectal Cancer

What is its impact on quality of life? Learn more: https://url.bcst.md/w4j

11/06/2023

3-Year Overall Survival With Tebentafusp in Previously Untreated Advanced Uveal Melanoma

Read more about results presented at : https://url.bcst.md/56p

11/03/2023

ACS Releases Updated Lung Cancer Screening Guideline

Learn more: https://url.bcst.md/amo

11/02/2023

Advanced NSCLC: Adding a Bispecific Antibody to Chemotherapy in First-Line Treatment'

Learn more about the PAPILLON trial, presented at : https://url.bcst.md/ffm

11/01/2023

Sotorasib Plus Panitumumab in KRAS G12C–Mutated Advanced Colorectal Cancer

Learn more about the CodeBreaK 300 trial, presented at : https://url.bcst.md/mok

10/31/2023

Biochemically Recurrent Prostate Cancer: Comparison of Three Regimens

Learn more about the EMBARK trial: https://url.bcst.md/oqc

10/30/2023

Jonathan D. Spicer, MD, PhD, on Early-Stage NSCLC: Survival Results With Pembrolizumab

Watch now: https://url.bcst.md/ki8

10/30/2023

Gastric and GEJ Adenocarcinomas: Perioperative Chemoimmunotherapy Regimen

Read more: https://url.bcst.md/kns

10/27/2023

Tina Cascone, MD, PhD, on NSCLC: Phase III Results on Nivolumab, Chemotherapy, and Surgery

Watch now: https://url.bcst.md/995

10/27/2023

FDA Approves Ivosidenib for Myelodysplastic Syndromes

Read more about the approval: https://url.bcst.md/2zr

10/26/2023

HERTHENA-Lung01: Antitumor Activity Shown With HER3-DXd in EGFR-Mutated NSCLC

Learn more: https://url.bcst.md/187

10/25/2023

PSMAfore: Lutetium Lu-177 Vipivotide Tetraxetan in Metastatic Prostate Cancer

Read more on findings presented at : https://url.bcst.md/hnn

10/24/2023

Cabozantinib for Pretreated Patients With Advanced Neuroendocrine Tumors: CABINET Trial

Data presented at : https://url.bcst.md/96r

10/23/2023

Pre- and Postsurgical Immunotherapy Improves Outcomes for Patients With Resectable Early-Stage NSCLC

Data presented at : https://url.bcst.md/ebm

10/20/2023

Blood-Based Testing for Multicancer Early Detection

Learn more about results from the PATHFINDER study: https://url.bcst.md/x9w

10/19/2023

Addition of Berzosertib to Topotecan in Relapsed SCLC

Read more about results from a phase II trial: https://url.bcst.md/bvm

10/18/2023

Tumor Debulking in Patients With Metastatic Colorectal Cancer

Read more about a novel study published in JNCCN: https://url.bcst.md/w4j

10/17/2023

FDA Approves Adjuvant Nivolumab for Stage IIB/IIC Melanoma

Learn more: https://url.bcst.md/lrf

10/17/2023

FDA Approves Encorafenib With Binimetinib for Metastatic BRAF V600E–Mutated NSCLC

Learn more: https://url.bcst.md/h40

10/16/2023

Chemical Hair Relaxers May Increase Risk of Uterine Cancer Among Black Women

Learn more: https://url.bcst.md/wdj

10/13/2023

FDA Authorizes Novel Liver Cancer Treatment

The FDA has granted marketing authorization to a novel system for the treatment of liver tumors using histotripsy. Learn more: https://url.bcst.md/3af

10/12/2023

Tracking the Progress Being Made in the Treatment of Breast Cancer and the Challenges Ahead

A Conversation With Jame Abraham, MD, FACP: https://url.bcst.md/9p9

Address

Huntington, NY

Website

www.ascopost.com

Alerts

Be the first to know and let us send you an email when The ASCO Post posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Videos

Gilberto de Lima Lopes, Jr, MD, MBA, and Oladimeji Akinboro, MD, MPH, on NSCLC: Outcomes of Anti–PD-(L)1 Therapy With or Without Chemotherapy in the First-Line Setting

Gilberto de Lima Lopes, Jr, MD, MBA, and Oladimeji Akinboro, MD, MPH, on #NSCLC: Outcomes of Anti–PD-(L)1 Therapy With or Without Chemotherapy in the First-Line Setting #lungcancer #immunotherapy #ASCO22

Thomas Powles, MD, PhD, and Jonathan E. Rosenberg, MD, on Urothelial Carcinoma: Long-Term Outcomes With Enfortumab Vedotin-ejfv vs Chemotherapy

Thomas Powles, MD, PhD, and Jonathan E. Rosenberg, MD, on #UrothelialCarcinoma: Long-Term Outcomes With #EnfortumabVedotin-ejfv vs Chemotherapy #ASCO22

Manali I. Patel, MD, MPH, on Equitable, Value-Based Care: The Effectiveness of Community Health Worker–Led Interventions

Manali I. Patel, MD, MPH, on Equitable, Value-Based Care: The Effectiveness of Community Health Worker–Led Interventions #ASCO22

Sue S. Yom, MD, PhD, on Oropharyngeal Cancer and the Feasibility of a Cell-Free DNA Plasma Assay

Sue S. Yom, MD, PhD, on #OropharyngealCancer and the Feasibility of a Cell-Free #DNA Plasma Assay #ASCO22

Alicia K. Morgans, MD, MPH, and Ian D. Davis, PhD, MBBS, on Prostate Cancer: Updated Overall Survival Outcomes With Enzalutamide

Alicia K. Morgans, MD, MPH, and Ian D. Davis, PhD, MBBS, on #ProstateCancer: Updated Overall Survival Outcomes With #Enzalutamide #ASCO22

Gilberto de Lima Lopes, Jr, MD, MBA, and Matthew Krebs, PhD, on NSCLC: Updated Results With Amivantamab-vmjw

Gilberto de Lima Lopes, Jr, MD, MBA, and Matthew Krebs, PhD, on #NSCLC: Updated Results With Amivantamab-vmjw #lungcancer #ASCO22

Ann H. Partridge, MD, MPH, and Véronique Diéras, MD, on the Future of Cytotoxic Therapy: Antibody-Drug Conjugates?

Ann H. Partridge, MD, MPH, and Véronique Diéras, MD, on the Future of Cytotoxic Therapy: #AntibodyDrugConjugates? #ASCO22

Erika Hamilton, MD, on Metastatic Breast Cancer: Safety Follow-up Data on T-DXd vs T-DM1

Erika Hamilton, MD, on #MetastaticBreastCancer: Safety Follow-up Data on #TDXd vs #TDM1 #ASCO22

12/06/2023

12/05/2023

12/05/2023

12/04/2023

12/01/2023

11/30/2023

11/29/2023

11/28/2023

11/27/2023

11/24/2023

11/23/2023

11/22/2023

11/21/2023

11/20/2023

11/16/2023

11/10/2023

11/09/2023

11/08/2023

11/07/2023

11/06/2023

11/03/2023

11/02/2023

11/01/2023

10/31/2023

10/30/2023

10/30/2023

10/27/2023

10/27/2023

10/26/2023

10/25/2023

10/24/2023

10/23/2023

10/20/2023

10/19/2023

10/18/2023

10/17/2023

10/17/2023

10/16/2023

10/13/2023

10/12/2023

Address

Website

Alerts

Videos

Gilberto de Lima Lopes, Jr, MD, MBA, and Oladimeji Akinboro, MD, MPH, on NSCLC: Outcomes of Anti–PD-(L)1 Therapy With or Without Chemotherapy in the First-Line Setting

Thomas Powles, MD, PhD, and Jonathan E. Rosenberg, MD, on Urothelial Carcinoma: Long-Term Outcomes With Enfortumab Vedotin-ejfv vs Chemotherapy

Manali I. Patel, MD, MPH, on Equitable, Value-Based Care: The Effectiveness of Community Health Worker–Led Interventions

Sue S. Yom, MD, PhD, on Oropharyngeal Cancer and the Feasibility of a Cell-Free DNA Plasma Assay

Alicia K. Morgans, MD, MPH, and Ian D. Davis, PhD, MBBS, on Prostate Cancer: Updated Overall Survival Outcomes With Enzalutamide

Gilberto de Lima Lopes, Jr, MD, MBA, and Matthew Krebs, PhD, on NSCLC: Updated Results With Amivantamab-vmjw

Ann H. Partridge, MD, MPH, and Véronique Diéras, MD, on the Future of Cytotoxic Therapy: Antibody-Drug Conjugates?

Erika Hamilton, MD, on Metastatic Breast Cancer: Safety Follow-up Data on T-DXd vs T-DM1

Shortcuts

Share

Category